- Home
- TLSI vs DOUG Comparison
TLSI vs DOUG Comparison
Compare TLSI & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- DOUG
- Stock Information
- Founded
- TLSI 2010
- DOUG 1911
- Country
- TLSI United States
- DOUG United States
- Employees
- TLSI N/A
- DOUG N/A
- Industry
- TLSI Medical Specialities
- DOUG Building operators
- Sector
- TLSI Health Care
- DOUG Real Estate
- Exchange
- TLSI Nasdaq
- DOUG Nasdaq
- Market Cap
- TLSI 166.8M
- DOUG 166.2M
- IPO Year
- TLSI N/A
- DOUG N/A
- Fundamental
- Price
- TLSI $4.48
- DOUG $1.84
- Analyst Decision
- TLSI Strong Buy
- DOUG
- Analyst Count
- TLSI 3
- DOUG 0
- Target Price
- TLSI $12.67
- DOUG N/A
- AVG Volume (30 Days)
- TLSI 74.0K
- DOUG 663.4K
- Earning Date
- TLSI 11-12-2024
- DOUG 11-05-2024
- Dividend Yield
- TLSI N/A
- DOUG N/A
- EPS Growth
- TLSI N/A
- DOUG N/A
- EPS
- TLSI N/A
- DOUG N/A
- Revenue
- TLSI $24,736,000.00
- DOUG $951,674,000.00
- Revenue This Year
- TLSI $61.24
- DOUG $3.85
- Revenue Next Year
- TLSI $47.32
- DOUG $17.40
- P/E Ratio
- TLSI N/A
- DOUG N/A
- Revenue Growth
- TLSI 67.75
- DOUG N/A
- 52 Week Low
- TLSI $3.32
- DOUG $1.00
- 52 Week High
- TLSI $10.42
- DOUG $3.16
- Technical
- Relative Strength Index (RSI)
- TLSI 32.54
- DOUG 51.03
- Support Level
- TLSI $4.54
- DOUG $1.42
- Resistance Level
- TLSI $5.08
- DOUG $2.05
- Average True Range (ATR)
- TLSI 0.38
- DOUG 0.15
- MACD
- TLSI -0.04
- DOUG 0.00
- Stochastic Oscillator
- TLSI 5.26
- DOUG 67.20
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.